Ghent, Belgium – June 15, 2026 – Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the Endocrine Society’s Annual Meeting (ENDO) 2026. The data support CFTX-2034 as a potential first-in-class therapy for PBH, a serious…
Bank of Spain-regulated card issuer combines human-led and agentic AI pentesting to surface business logic risk and meet regulatory traceability requirements Bank of Spain-regulated card issuer combines human-led and agentic AI pentesting to surface business logic risk and meet regulatory traceability requirements
Þann 12. mars 2026 var tilkynnt um undirritun Sýnar hf. (Sýn) og Ása hf. (Ása) á skilmálaskjali um kaup Ása á vef- og útvarpsmiðlum Sýnar. Frestur samkvæmt skilmálaskjalinu til að ljúka gerð endanlegs kaupsamnings og annarrar nauðsynlegrar skjalagerðar er nú liðinn án þess að kaupsamningur hafi verið undirritaður. Samkomulag um einkarétt Ása til samningaviðræðna er…